Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma / 国际肿瘤学杂志
Journal of International Oncology
; (12): 381-384, 2021.
Article
de Zh
| WPRIM
| ID: wpr-907550
Bibliothèque responsable:
WPRO
ABSTRACT
The new immune and targeted therapy medicines of multiple myeloma and recurrence of refractory multiple myeloma mainly include immunomodulatory drugs, proteasome inhibitors, monoclonal antibody, immune monitoring point inhibitors, histone deacetylase and chimeric antigen receptor. Although the emergence of new drugs and the application of autologous hematopoietic stem cell transplantation have significantly improved the prognosis of patients, more effective treatment methods and treatment strategies are still required to deal with the adverse reactions and the condition of recurrence during treatment.
Texte intégral:
1
Base de données:
WPRIM
Langue:
Zh
Journal:
Journal of International Oncology
Année:
2021
Type de document:
Article